Hong Kong Leisure Stock News

Innovent Biologics (SEHK:1801) is in focus after presenting early results from its first-in-human Phase 1 trial of IBI3016, a new RNA interference treatment for hypertension, at the American Heart Association scientific sessions. See our latest analysis for Innovent Biologics. Strong early data from Innovent’s novel RNAi hypertension treatment has certainly kept the spotlight on the stock, especially after a string of robust product launches and revenue growth. While the share price return...

China Zheshang Bank Co., Ltd recently announced its earnings for the nine months ended September 30, 2025, reporting net interest income of CNY 34,438 million and net income of CNY 11,668 million, both lower than the previous year’s figures. This decline in core profitability metrics highlights a challenging period for the bank, with earnings per share also slipping year over year. We’ll take a closer look at how the year-over-year drop in net income impacts China Zheshang Bank’s investment...

Lenovo PCCW Solutions (LPS) recently launched a Next-Gen IT Ecosystem, collaborating with 18 major technology partners to deliver integrated digital transformation services for enterprises across Hong Kong and Asia Pacific. This initiative brings together strengths in application software, cybersecurity, office automation, and infrastructure, positioning PCCW and its partners to support Hong Kong's ambitions as a leading innovation and technology hub. We'll examine how the partnership-driven...

Everest Medicines (SEHK:1952) has announced a new agreement with Visara Inc., gaining exclusive rights to develop and commercialize VIS-101 across Greater China and parts of Asia. This deal marks Everest's move into ophthalmology and broadens its late-stage product pipeline. See our latest analysis for Everest Medicines. Everest Medicines’ latest move into ophthalmology comes as the company’s momentum shifts, with the recent 1-year total shareholder return reaching an impressive 32.84%. The...

Yuexiu Property (SEHK:123) just released its October 2025 sales update, revealing an 8% decrease in contracted sales value and a 42% drop in gross floor area compared to the same period last year. See our latest analysis for Yuexiu Property. Yuexiu Property’s latest sales update arrives as the share price remains under pressure, closing at HK$4.70 after a year marked by persistent weakness. While recent news showed a modest pickup in year-to-date contracted sales value, overall momentum has...

On November 5, 2025, Ailux announced a platform-based collaboration with Eli Lilly to expedite the discovery and development of bispecific antibodies using Ailux’s AI-powered engineering platform, with the deal including upfront and near-term payments in the double-digit millions and potential milestones up to US$345 million. This partnership highlights the value of Ailux’s AI technology in drug discovery and represents a significant validation from an established pharmaceutical...

Jiangsu Expressway (SEHK:177) released its earnings for the nine months ending September 30, 2025, with both revenue and net income coming in lower than the same period last year. This update offers a fresh perspective on the company’s current trajectory. See our latest analysis for Jiangsu Expressway. After updating its bylaws and posting weaker nine-month results, Jiangsu Expressway’s share price has still climbed noticeably, recording an 18.5% year-to-date return. Long-term momentum...

Sun Art Retail Group Limited reported its half-year results for the period ended September 30, 2025, with sales declining to CNY 30.50 billion from CNY 34.71 billion a year earlier and a swing from net income of CNY 206 million to a net loss of CNY 123 million. This reversal from profit to loss marks a significant shift in the company's recent financial performance and signals increased challenges in its core retail operations. We'll explore how the return to net loss and falling sales...

Global markets have recently faced a downturn, with U.S. stocks snapping a three-week winning streak due to tech sell-offs and concerns over AI spending, while consumer sentiment has hit its lowest point since 2022. Despite these challenges, certain investment opportunities remain attractive, particularly in the realm of penny stocks—an area that continues to hold potential for those willing to explore smaller or newer companies with solid financial foundations. Though the term 'penny stock'...

China Communications Construction Company Limited recently reported earnings for the nine months ended September 30, 2025, with revenue and net income decreasing to CNY 513.92 billion and CNY 13.65 billion respectively compared to the prior year. The company announced both an interim dividend and a plan to distribute 20% of its first-half net profit as cash dividends, reinforcing its focus on rewarding shareholders despite lower earnings. With a new dividend plan signaling commitment to cash...

Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...

Key Insights Vtech Holdings' estimated fair value is HK$92.36 based on 2 Stage Free Cash Flow to Equity Current share...

Dekon Food and Agriculture Group recently announced plans to convert its domestic shares into H shares, subject to regulatory approval from the China Securities Regulatory Commission and the Hong Kong Stock Exchange. The company also reported an increase in pig sales volume for October 2025, even as average selling prices for market hogs declined, providing insights into ongoing trends in the agriculture sector. We'll explore how the move to improve share liquidity through H share conversion...

Ascletis Pharma (SEHK:1672) has captured attention after sharing new Phase Ib data for its ASC30 oral tablet and injection. The results demonstrated up to 7% placebo-adjusted mean body weight reduction and strong safety signals, with only mild gastrointestinal issues reported. See our latest analysis for Ascletis Pharma. Ascletis Pharma’s rapid progress in its clinical obesity programs has sparked a flurry of investor enthusiasm, helping fuel a 243.5% year-to-date share price return. While...

Shandong Weigao Group Medical Polymer Company Limited announced on November 3, 2025, that unaudited third quarter revenue reached approximately RMB 3.26 billion, a 2.6% year-on-year increase. This steady revenue growth offers an up-to-date indicator of market demand for the company's medical device portfolio across China and beyond. We'll explore how this sustained sales momentum contributes to Shandong Weigao Group Medical Polymer's investment narrative and operational outlook. These 13...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

As global markets face fluctuations, with concerns about elevated valuations and economic uncertainties in major regions like the U.S. and Europe, Asia presents intriguing opportunities for investors seeking value. In this environment, identifying undervalued stocks—those trading below their intrinsic worth—can be a strategic approach to potentially benefit from market inefficiencies and capture future growth prospects.

Grand Pharmaceutical Group (HKG:512) has had a rough week with its share price down 3.1%. However, a closer look at its...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

China Silver Group's (HKG:815) stock is up by a considerable 40% over the past three months. We wonder if and what role...

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Luxury industry in Hong Kong, you could be...

Q Technology (Group) (SEHK:1478) reported a year-on-year rise in October 2025 sales volumes for its camera and fingerprint modules, reflecting gains in mobile phone, IoT, and smart vehicle markets. The company also exited its Q Tech India stake. See our latest analysis for Q Technology (Group). Q Technology’s latest operational gains have added a shot of energy to its momentum story this year. Despite recent volatility, with a 1-day share price climb of 4.34% offsetting some of last week’s...

Key Insights 361 Degrees International's estimated fair value is HK$7.57 based on 2 Stage Free Cash Flow to Equity 361...

Key Insights The considerable ownership by retail investors in Jiangsu Recbio Technology indicates that they...